Critical Survey: Moolec Science (MLEC) & Its Rivals

Moolec Science (NASDAQ:MLEC) is one of 494 public companies in the “Biotechnology” industry, but how does it contrast to its rivals? We will compare Moolec Science to similar businesses based on the strength of its institutional ownership, analyst recommendations, earnings, profitability, dividends, risk and valuation.

Profitability

This table compares Moolec Science and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Moolec Science	-129.97%	-93.88%	-33.37%
Moolec Science Competitors	-7,340.74%	-106.26%	-28.29%

Risk & Volatility

Moolec Science has a beta of -0.54, suggesting that its share price is 154% less volatile than the S&P 500. Comparatively, Moolec Science’s rivals have a beta of 1.23, suggesting that their average share price is 23% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Moolec Science and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moolec Science	0	0	1	0	3.00
Moolec Science Competitors	981	2800	7014	101	2.57

Moolec Science presently has a consensus price target of $6.00, indicating a potential upside of 605.88%. As a group, “Biotechnology” companies have a potential upside of 20.22%. Given Moolec Science’s stronger consensus rating and higher probable upside, analysts clearly believe Moolec Science is more favorable than its rivals.

Institutional and Insider Ownership

0.1% of Moolec Science shares are held by institutional investors. Comparatively, 33.3% of shares of all “Biotechnology” companies are held by institutional investors. 19.9% of Moolec Science shares are held by company insiders. Comparatively, 20.4% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Moolec Science and its rivals top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Moolec Science	$5.63 million	-$7.31 million	-4.25
Moolec Science Competitors	$212.91 million	-$18.46 million	114.04

Moolec Science’s rivals have higher revenue, but lower earnings than Moolec Science. Moolec Science is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Summary

Moolec Science rivals beat Moolec Science on 7 of the 13 factors compared.

Moolec Science Company Profile

Moolec Science SA, a science-based food ingredient company, focuses on developing real animal proteins in plants using molecular farming. It offers Chymosin SPC, a dairy ingredient; GLA SONOVA, a nutritional oil; POORK+, a plant-based, animal meat free ingredient with porcine proteins in soybeans; and BEEF+, a meat replacement product. It operates in the United States, Europe, and South America. The company was founded in 2020 and is based in Luxembourg.